Unfold AI™, the FDA cleared prostate cancer management platform developed by Avenda Health, is now being used in a commercial setting at a renowned U.S. research hospital. The AI healthcare company is committed to advancing personalized prostate cancer care, enhancing patient outcomes, and preserving their quality of life.
Physicians at the research hospital, like Wayne Brisbane, MD, have embraced the technology in their practice. By merging patient-specific data from prostate imaging, biopsies, and pathology with deep-learning algorithms, Unfold AI creates a tailored cancer estimation map. This 3D, AI-generated map provides a visualization of the cancer location, enabling physicians to make more informed treatment decisions and plan interventions accordingly.
Dr. Leonard Marks, co-founder and Chief Medical Officer of Avenda Health, expressed his enthusiasm about the platform: “This is a major step forward for the prostate cancer community, and we are beyond thrilled to see a decade of hard work and research pay off. Our mission at Avenda Health is to create a better quality of life for prostate cancer patients and to give urologists a clearer view of the cancer so we can better treat our patients. Unfold AI will improve clinical care and decision making.”
Avenda Health’s mission is to make this state-of-the-art technology accessible to all physicians treating prostate cancer patients, with the goal of establishing a new standard of care. During clinical trials, guidance from Unfold AI prompted physicians to alter their treatment recommendations in 28% of cases, frequently opting for more localized treatment. The platform enables the selection of multiple treatment options, including active surveillance, whole gland treatments such as radical prostatectomy and radiation therapy, or soft tissue laser ablation with Avenda Health’s FocalPoint device.
Unfold AI obtained 510(k) clearance from the U.S. FDA in December 2022. For additional information about Avenda Health and its groundbreaking platform, visit avendahealth.com.